Suppr超能文献

用免疫刺激复合物进行口服或肠胃外免疫诱导Th1和Th2 CD4 + T细胞反应。

Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS.

作者信息

Maloy K J, Donachie A M, Mowat A M

机构信息

Department of Immunology, University of Glasgow, Western Infirmary, Scotland.

出版信息

Eur J Immunol. 1995 Oct;25(10):2835-41. doi: 10.1002/eji.1830251019.

Abstract

We examined the ability of oral or parenteral immunization with immune stimulating complexes containing ovalbumin (ISCOMS-OVA) to prime T cell proliferative and cytokine responses. A single subcutaneous immunization with ISCOMS-OVA primed potent antigen-specific proliferative responses in the draining popliteal lymph node, which were entirely dependent on the presence of CD4+ T cells. CD8+ T cells did not proliferate in vitro even in the presence of the appropriate peptide epitope and exogenous interleukin (IL)-2. Primed popliteal lymph node cells produced IL-2, IL-5 and interferon (IFN)-gamma, but not IL-4 when restimulated with OVA in vitro. Serum antigen-specific IgG1 and IgG2a antibody responses were also primed by subcutaneous immunization with ISCOMS-OVA, confirming the stimulation of both Th1 and Th2 cells in vivo. Spleen cells from subcutaneously primed mice produced a similar pattern of cytokines, indicating that disseminated priming had occurred. Oral immunization with ISCOMS-OVA also primed local antigen-specific proliferative responses in the mesenteric lymph node and primed an identical pattern of systemic cytokine responses in the spleen. The ability of ISCOMS to prime both Th1 and Th2 CD4+ T cell responses may be central to their potent adjuvant activities and confirm the potential of ISCOMS as future oral vaccine vectors.

摘要

我们检测了用含卵清蛋白的免疫刺激复合物(ISCOMS-OVA)进行口服或肠胃外免疫引发T细胞增殖和细胞因子反应的能力。单次皮下注射ISCOMS-OVA可在引流的腘淋巴结中引发有效的抗原特异性增殖反应,这些反应完全依赖于CD4+ T细胞的存在。即使存在合适的肽表位和外源性白细胞介素(IL)-2,CD8+ T细胞在体外也不增殖。当体外再次用OVA刺激时,引发的腘淋巴结细胞产生IL-2、IL-5和干扰素(IFN)-γ,但不产生IL-4。血清抗原特异性IgG1和IgG2a抗体反应也可通过皮下注射ISCOMS-OVA引发,证实了体内Th1和Th2细胞均受到刺激。皮下引发的小鼠的脾细胞产生了类似的细胞因子模式,表明已发生全身性引发。用ISCOMS-OVA进行口服免疫也可在肠系膜淋巴结中引发局部抗原特异性增殖反应,并在脾脏中引发相同模式的全身性细胞因子反应。ISCOMS引发Th1和Th2 CD4+ T细胞反应的能力可能是其强大佐剂活性的核心,并证实了ISCOMS作为未来口服疫苗载体的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验